This economic evaluation investigates the real-world cost-effectiveness of nirsevimab immunization in preventing respiratory syncytial virus (RSV)–related pediatric hospitalizations.
JAMA Pediatrics published a clinical update in Research Highlights on 13 Apr 2026. The item focuses on Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations. Open the detail page to review the full original feed content.